FASLG and ovarian carcinoma: Emerging evidence suggests that the downregulation of Fas ligand (FasL) expression is associated with acquired resistance to chemotherapeutic agents such as cisplatin [28]; cisplatin-resistant human ovarian cancer cells exhibit sustained suppression of FasL expression, thereby impairing apoptosis via the FAS pathway.